RayzeBio and Nimble Therapeutics plan to collaborate on the discovery and development of novel peptide-based radiopharmaceuticals for cancer treatment.
The partnership will allow RayzeBio to expand its radiopharmaceutical pipeline and develop multiple therapies simultaneously, it said.
RayzeBio will pay Nimble an undisclosed upfront amount, research reimbursements, and perhaps milestone payments and royalties. RayzeBio has exclusive rights to market any peptides discovered through the collaboration, it said.
